Eating Disorders & GLP-1 RAs


Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes. LP-1 RAs are now being used as an approved or off-label treatment for weight loss.

here is limited research available to help researchers, clinicians, and patients/consumers to understand the relationships between GLP-1 RAs and eating disorders (9). However, it is thought that GLP-1 RAs may negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information for clinicians, researchers, and patients/consumers to understand more about the link between GLP-1 RAs and eating disorders, including risks, physical impacts, psychological impacts, and practice recommendations.



« Back to Browse Resources

See also

Issue 62 I Comorbid Diabetes and Eating Disorders

NEDC e-Bulletin Editor’s NoteIn our work and training across the country, the National Eating Disorders Collaboration has seen an increasing interest in the topic of eating disorders and co-occurring diabetes.

Read more

RESET - A Conversation About Boys' Body Image

Australia's first digital body image program for boys, RESET is a digital education program designed to start a deeper conversation with boys about negative body image and eating disorders.

Read more

Stepped System of Care - Italian

La National Eating Disorders Collaboration (NEDC) ha messo insieme le conoscenze acquisite nel settore per oltre venti anni, insieme all'esperienza sul campo e allo sviluppo dei servizi, per creare un modello di cura graduato per i disturbi del comportamento alimentare (vedi Figura 1).

Read more